Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050845
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (306,679) | (356,346) |
| Sales and maturities of marketable securities | 541,167 | 568,082 |
| Purchases of property and equipment | (8,102) | — |
| Net cash provided by investing activities | 226,386 | 211,736 |
| Cash flows from financing activities: | ||
| Proceeds from exercise of common stock options | 5,441 | 10,381 |
| Net cash provided by financing activities | 5,441 | 10,381 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is Madrigal Pharmaceuticals, Inc.'s capex?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported capex of $4.25M in Q2 2026.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s capex?
- Over 3 years (2021 to 2024), Madrigal Pharmaceuticals, Inc.'s capex has grown at a 91.2% compound annual growth rate (CAGR), from $209K to $1.46M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Madrigal Pharmaceuticals, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude